New eczema foam shows promise for kids in Late-Stage trial
NCT ID NCT07184645
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase 3 trial tests a medicated foam called OPA-15406 (difamilast) for atopic dermatitis (eczema) in children aged 2 and older, and infants under 2. About 198 participants will apply the foam twice daily for 8 weeks. The main goal is to see if the foam clears or nearly clears skin symptoms better than a foam without medicine.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- OPA-15406 (difamilast) foam
- What this could lead to
- If successful, this could provide a new topical treatment option for children and infants with atopic dermatitis, potentially improving skin symptoms and quality of life.
- What could go wrong
- This is still an early-stage Phase 3 trial with only 198 participants, so results may not apply to all patients. The treatment may not prove superior to the vehicle (placebo) foam, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sumire Dermatology Clinic
Tokyo, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can ozonated oil soothe eczema in kids?
- Can a Skin-Repairing cream soothe eczema?
- Can a new antibody calm severe eczema?
- Microscopic skin scans may reveal how a new eczema drug reshapes the skin
- Menthol gloves may offer quick itch relief for eczema sufferers
- One pill may tame both itchy skin and stubborn liver disease